Magrolimab

莫洛利单抗

Report date: 2025/05/20 16:56:12

Base Information

Drug NameMagrolimab
Drug Alias NameONO-7913Hu5F9-G4GS-47215F9
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesUrinary Bladder Neoplasms +[25] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoGilead Sciences IncStanford University +[5] 
Inactive CompaniesF. Hoffmann-La Roche LtdLeipzig UniversityThe University Of Texas MD Anderson Cancer Center +[5] 
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsBrain Neoplasms +[14] 
Inactive IndicationsMyelodysplastic SyndromesOvarian NeoplasmsTriple Negative Breast Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksN/A